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Abstract
Background: Critically ill trauma patients with severe injuries are at high risk for venous thromboembolism (VTE) and
bleeding simultaneously. Currently, the optimal VTE prophylaxis strategy is unknown for trauma patients with a
contraindication to pharmacological prophylaxis because of a risk of bleeding.
Methods and Findings: Using decision analysis, we estimated the cost effectiveness of three VTE prophylaxis strategies—
pneumatic compression devices (PCDs) and expectant management alone, serial Doppler ultrasound (SDU) screening, and
prophylactic insertion of a vena cava filter (VCF)—in trauma patients admitted to an intensive care unit (ICU) with severe
injuries who were believed to have a contraindication to pharmacological prophylaxis for up to two weeks because of a risk
of major bleeding. Data on the probability of deep vein thrombosis (DVT) and pulmonary embolism (PE), and on the
effectiveness of the prophylactic strategies, were taken from observational and randomized controlled studies. The
probabilities of in-hospital death, ICU and hospital discharge rates, and resource use were taken from a population-based
cohort of trauma patients with severe injuries (injury severity scores .12) admitted to the ICU of a regional trauma centre.
The incidence of DVT at 12 weeks was similar for the PCD (14.9%) and SDU (15.0%) strategies, but higher for the VCF (25.7%)
strategy. Conversely, the incidence of PE at 12 weeks was highest in the PCD strategy (2.9%), followed by the SDU (1.5%)
and VCF (0.3%) strategies. Expected mortality and quality-adjusted life years were nearly identical for all three management
strategies. Expected health care costs at 12 weeks were Can$55,831 for the PCD strategy, Can$55,334 for the SDU screening
strategy, and Can$57,377 for the VCF strategy, with similar trends noted over a lifetime analysis.
Conclusions: The attributable mortality due to PE in trauma patients with severe injuries is low relative to other causes of
mortality. Prophylactic placement of VCF in patients at high risk of VTE who cannot receive pharmacological prophylaxis is
expensive and associated with an increased risk of DVT. Compared to the other strategies, SDU screening was associated
with better clinical outcomes and lower costs.
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Venous thromboembolism (VTE), including deep vein throm-
bosis (DVT) and pulmonary embolism (PE), are common
complications that are associated with high rates of morbidity and
mortality in trauma patients recovering from severe injuries. The
risk of developing VTE is dependent on various factors including
patient age and the type and severity of injury [1,2]. On average,
trauma patients have a 58% risk of distal DVT and an 18% risk of
proximalDVT[2]. Ifleftuntreated,halfof thosewho presentwitha
proximal DVT will develop a clinically important PE, and of those,
2%–3% will die as a consequence of the PE [3,4].
Prevention of VTE in trauma patients, who are at high risk for
thrombosis and bleeding simultaneously, poses a major challenge
[1]. As many as 22% of trauma patients have ongoing bleeding or
injuries and are at high risk for serious bleeding complications
[1,5]. Furthermore, up to 86% of multiple trauma patients sustain
injuries to the lower extremities, which may preclude the effective
use of pneumatic compression devices (PCDs) [1]. The Eastern
Association for the Surgery of Trauma (EAST) recommends
consideration of vena cava filter (VCF) insertion in patients
without documented DVT or PE who are at high risk of VTE and
who cannot receive pharmacological prophylaxis [1]. Other
professional trauma associations, including the British Trauma
Society, Trauma Association of Canada, and the Australasian
Trauma Society, provide no formal VTE prophylaxis guidelines.
Nevertheless, a retrospective review of VCF insertions at 21 North
American trauma centres suggests that significant variation exists
in the frequency that VCFs are used in different trauma centres,
with VCFs inserted twice as frequently at low-volume trauma
centres as at high-volume centres [6]. VCFs are known to be
effective at preventing PE in patients with known DVT [7], but
their effectiveness and safety as prophylactic therapy for
prevention of PE in patients at risk for DVT has not been tested
in a randomized controlled trial. This is an important concern
given that the use of VCF increases the risk of DVT [8], and that
DVTs may result in long-term complications, including severe
venous stasis and ulceration [9,10]. Currently, the optimal
prophylaxis strategy for patients at high risk of VTE and a
contraindication to pharmacological prophylaxis is unknown.
Considering the estimated cost of VCF (Can$3,600 per insertion
and removal), the potential frequency of its use [11], and the
uncertainty regarding its effectiveness and safety [12,13], decision-
makers must determine its optimal use.
We collected clinical and cost information on a cohort of
trauma patients admitted to an intensive care unit (ICU) with
severe injuries who were believed to have a contraindication to
pharmacological VTE prophylaxis for two weeks because of a risk
of major bleeding. Based on this cohort of patients, using decision
analysis, we estimated the cost effectiveness of three VTE
prophylaxis strategies: PCDs and expectant management alone,
serial Doppler ultrasound (SDU) screening, and prophylactic
insertion of a VCF.
Methods
Study Design
Using decision analysis and an analytic horizon of a lifetime, we
calculated the cost effectiveness of three different VTE prophylaxis
strategies in trauma patients with severe injuries admitted to the
ICU who were believed to have a contraindication to pharma-
cological VTE prophylaxis for up to 2 wk because of a risk of
major bleeding. The three strategies considered were: (1) PCDs
and expectant management alone; (2) SDU screening; and (3)
prophylactic insertion of a VCF.
We modelled the analysis over the course of 30 y since the
average age of our severely injured cohort was 40 y. Given the
importance of short-term clinical outcomes in trauma patients, we
also estimated the incidence of DVTs, PEs, deaths, and health care
costs at 12 wk for the three strategies. In base case analyses, we
took the perspective of the health care purchaser. Costs and
quality-adjusted life years (QALYs) were discounted at 5%
annually, and costs were inflated to 2007 Canadian dollars
(Can$1.00=US$0.96) using the Bank of Canada online inflation
calculator.
Cohort of Trauma Patients on Which the Decision
Analysis Was Based
Guidelines published by EAST and the Brain Trauma
Foundation suggest that trauma patients with intracranial
haemorrhage, ocular injury with associated haemorrhage, solid
intra-abdominal injury (i.e., liver, spleen, kidney), or pelvic or
retroperitoneal hematoma requiring transfusion are at increased
risk of bleeding complications for 5–10 d following injury [1,14].
Patients who have ongoing bleeding, are at high risk of bleeding,
or will not tolerate even minor bleeding have a contraindication to
pharmacological VTE prophylaxis. Estimates of the risk of death
and cost of care in these subgroups of trauma patients with severe
injuries are unknown. Therefore, we identified a cohort of trauma
patients admitted to ICU with severe head/neck and abdomen/
pelvis injuries who, according to the EAST and Brain Trauma
Foundation guidelines, would be at risk of serious bleeding
complications and would be likely to have a contraindication to
pharmacological VTE prophylaxis to obtain accurate estimates of
mortality and direct health care costs. Therefore, we undertook a
cohort study to obtain accurate estimates of mortality and direct
health care costs for trauma patients admitted to ICU with severe
head/neck and abdomen/pelvis injuries that, according to the
EAST and Brain Trauma Foundation guidelines, would be at risk
of serious bleeding complications and would be likely to have a
contraindication to pharmacological VTE prophylaxis. The
Conjoint Health Research Ethics Board at the University of
Calgary and Calgary Health Region approved this study.
Foothills Medical Centre is the sole regional adult trauma
referral centre in Southern Alberta (population 1.5 million) and
admits over 1,000 patients each year with severe injuries (injury
severity score.12) [15]. We based our analysis on a cohort of
adult (age$15 y) patients admitted to the trauma centre’s
multisystem ICU between 01 April 2001 and 28 March 2006
with an admitting diagnosis of traumatic injury who were not
treated with prophylactic VCF insertion. Patients were included if
their admitting diagnosis was a traumatic injury, their injury
severity score (ISS) was greater than 12 and their head/neck or
abdomen/pelvis abbreviated injury scale (AIS) score was 3 or
greater [15]. We selected this cohort of trauma patients because
their injuries most closely approximated those identified by the
EAST and Brain Trauma Foundation guidelines as being at high
risk of serious bleeding complications and a potential contraindi-
cation to pharmacological VTE prophylaxis (Table 1) [1,14].
Prophylaxis Strategies
Patients treated with PCDs received expectant management for
VTE during the first 2 wk of hospital admission unless a DVT or
PE was detected clinically and subsequently diagnosed radio-
graphically. In the second strategy, all patients received PCDs as
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hospitalization beginning in the first week of ICU admission.
Patients with a positive test (true positive or false positive) were
assumed to have a DVT. In the final strategy, patients underwent
prophylactic VCF insertion within 48 h of admission. Patients who
died within 48 h of admission were assumed to have died before
VCF insertion and from causes unrelated to VTE.
In all three strategies, based on recommendations from the
EAST guidelines that high risk trauma patients were at risk of
bleeding for 5–10 d following initial injury, contraindications to
pharmacological VTE prophylaxis were assumed to resolve after
2 wk of hospitalization, and patients in each strategy then initiated
prophylaxis with low-molecular weight heparin [1]. Patients
diagnosed with a DVT in the PCD and SDU screening strategies
were treated with VCF insertion during the first 2 wk of
hospitalization and with therapeutic anticoagulation thereafter.
In the VCF strategy patients were assumed to receive therapeutic
anticoagulation during their hospital stay only if they developed a
PE and not just a DVT, because the risk of a PE with a VCF is
very low. All patients diagnosed with VTE after 2 wk were
assumed to receive initial anticoagulation with low-molecular
weight heparin and subsequent ongoing anticoagulation with
warfarin for a 1-y period after hospital discharge.
Markov Analysis
Among the different types of decision analysis, the most
appropriate method to model recurring events and transitions
between different health states is Markov analysis [16]. Since our
analysis modelled recurring weekly risks of DVT, death, and
transition from the ICU to the hospital and subsequently home,
we selected Markov analysis (Data Pro software, TreeAge
software, Williamstown) (Figure 1). Through the use of multiple
health states and decision analytic software, the probabilities of
transitions between health states can be allowed to vary over the
course of weekly Markov cycles [16]. In Markov analysis, a model
is constructed, ideally using costs and clinical outcome data from
an actual patient cohort (cohort of trauma patients in our study),
which replicates these clinical outcomes and costs. Next, tests or
treatments (prophylaxis strategies in our study) are overlaid on the
model, and the subsequent impact on clinical outcomes and costs
can be accurately estimated [16]. Each health state can also be
assigned a utility (i.e., a measure of overall quality of life), and the
cumulative utility spent in each state can be summed to calculate
the QALYs of each strategy. The starting point of our model was
the cohort of trauma patients with severe injuries who were
believed to have up to a 2-wk contraindication to pharmacologic
prophylaxis.
Clinical Effects
Probability of DVT. The probability of proximal DVT was
taken from an observational study [2] and a randomized trial [17]
comparing low-dose heparin with low-molecular weight heparin as
prophylaxis against VTE after major trauma. This probability,
which was used for the non-VCF strategies, was taken to be 6.4%
weekly for the initial 2 wk in patients receiving no
pharmacological VTE prophylaxis, and 3.1% weekly thereafter
(while receiving low-molecular weight heparin as prophylaxis)
(Table 2) [2,17]. In all strategies, we assumed that 50% of all
DVTs were asymptomatic [18], and would only be diagnosed in
the SDU strategy or after development of a clinical PE. Patients
with an asymptomatic undiagnosed DVT were assumed not to
receive therapeutic anticoagulation.
Probability of PE. The probability of a patient with an
undiagnosed DVT developing a PE was estimated to be 50% [19].
Table 1. Patient characteristics, costs, and outcomes.
Characteristic Subcategory
All Patients
(n=1,015)
Age, y 39.3 (38.1–40.5)
Male, n (%) 775 (76)
Mechanism of injury, n (%) Motor vehicle
collision
610 (60)
Fall 224 (22)
Violence 106 (10)
Other 76 (7)
Glasgow coma score Scene 6.9 (6.7–7.1)
Emergency
department
6.2 (6.0–6.5)
Injury severity score 30.5 (29.8–31.2)
Abbreviated injury
severity score
a
Head/neck 4.3 (4.2–4.3)
Face 2.0 (2.0–2.1)
Chest 3.0 (2.9–3.1)
Abdomen/pelvis 3.3 (3.2–3.4)
Extremities 2.6 (2.6–2.7)
External 1.1 (1.0–1.1)
Ethanol screen
positive, n (%)
317 (31)
APACHE II score 20.7 (20.2–21.1)
SOFA score
b 12.6 (12.3–12.9)
TISS score 29.7 (29.0–30.5)
Surgery during hospital
stay, n (%)
342 (34)
Duration of mechanical
ventilation, median
(interquartile range), d
3 (1–9)
Length of stay, median
(interquartile range), d
ICU 5 (2–11)
Hospital 17 (7–44)
Mortality, n (%) 48 h from admission 122 (12)
ICU discharge 232 (23)
Hospital discharge 242 (24)
Cost of care, median
(interquartile range),
Can$
ICU 9,645 (4,097–25,966)
Ward 23,378 (11,026–
49,535)
Total hospital stay 35,282 (18,196–
74,168)
Annual cost of care for
hospital survivors
(years 1–3), Can$
Year 1 3,460 (2,139–4,780)
Year 2 1,100 (453–1,746)
Year 3 537 (169–905)
Data are presented as means (95% confidence intervals) unless otherwise
indicated.
aAbbreviated injury severity scores are provided for patients with documented
injuries involving the head/neck (n=946), face (n=335), chest (n=528),
abdomen/pelvis (n=345), extremities (n=417), and external (n=238) body
regions.
bSOFA (Sequential Organ Failure Assessment) score calculated at 07:00 on first
day of admission to the ICU.
APACHE, Acute Physiology and Chronic Health Evaluation; TISS, Therapeutic
Intervention Scoring System.
doi:10.1371/journal.pmed.1000098.t001
VTE Prophylaxis in Trauma Patients
PLoS Medicine | www.plosmedicine.org 3 June 2009 | Volume 6 | Issue 6 | e1000098In patients with a known DVT who were treated with therapeutic
anticoagulation the risk of developing a PE was documented as 4.8%,
taken from a randomized trial [7]. Patients developing a PE had a
subsequent early risk of PE-related death of 2.5% (Table 2) [4].
Clinical effects of VCF insertion. A systematic review of
the literature was performed to determine the key probabilities of
developing a proximal DVT, PE, or adverse event after
prophylactic insertion of a VCF (see Text S1 for methods and
full results, also Figure S1; Tables S1 and S2). A single randomized
control trial was selected to derive probabilities because of its
methodological rigor. In patients who had insertion of a VCF, the
probability for development of in-hospital DVT were estimated to
be 1.87-fold higher than the incidence of DVT in the non-VCF
strategies, while the risk of developing a PE if a DVT developed
was documented as 1.1% (Table 2) [7].
Mortality. The ICU and hospital weekly risk of death was
estimated from the cohort study (Table 1). The risk of death for
patients with DVTs was assumed to be higher only among those
who developed a PE [20,21]. Based on the results of our systematic
review, we estimated a small (0.12%) risk of VCF insertion-related
mortality [22]. After hospital discharge, the risk of death over 2 y
was taken from an observational study documenting the survival of
critically ill trauma patients discharged from hospital [23]. After
2 y, we assumed that survivors would return to the baseline risk of
age-adjusted mortality for Canadians. We assumed similar
mortality rates for patients discharged from hospital with VTE,
compared to those with no VTE [20,21].
Length of ICU and hospital stay. Within our cohort study,
consistent with other published reports, length of stay was longer
for patients who developed DVT and PE, although it is unclear
whether VTE causes increased lengths of stay. Therefore, using
content experts and a Delphi method, we estimated that ICU
patients developing DVT or PE, and hospital patients developing
DVT or PE, would have their discharge delayed by 2, 3, 5, and
7 d, respectively [24]. We assumed that the length of stay would
not be increased for patients with a VCF who developed a DVT,
given that they are at lower risk of PE, an assumption favourable
to the prophylactic VCF strategy.
Other clinical effects. For diagnostic screening of proximal
DVT with SDU, the sensitivity and specificity were derived from
data published by EAST and reported to be 61% and 97%
respectively in patients with serious traumatic injuries (Table 2) [1].
Utility estimates for long-term survivors of trauma were estimated
using observational studies and were assumed to be lower for
patients that developed severe post-thrombotic syndrome [9,23].
Health Care Costs
We estimated the cost of VCF insertion and SDU testing (both
including physician fees) to be Can$2,310 and Can$386,
respectively (Table 3). The cost of prophylactic low-molecular
weight heparin and therapeutic anticoagulation was based on the
Alberta Drug Benefit List (Table 3). We assumed that all patients
receiving therapeutic anticoagulation would be at risk of major
bleeding (3.9%) [7], and estimated the cost of managing this
complication on a study from Heyland et al. [25]. Weekly ICU
and trauma ward costs were obtained from the cohort of trauma
patients, consistent with prior studies (Table 1) [26]. Mean weekly
physician billings for these patients in ICU (Can$3,055) and on the
Ward (Can$280) were obtained from previous estimates for a
similar patient cohort (Table 3) [26]. The cost of non-VTE-related
Figure 1. Model of three venous thromboembolism prophylaxis strategies.
doi:10.1371/journal.pmed.1000098.g001
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discharge were estimated for the cohort of trauma patients. The
cost of both PE and DVT related readmissions was taken from
Aujesky et al. [27]. Outpatient VTE management costs were
calculated on the basis of all relevant nursing, medication, lab,
support staff, and supply-related costs, while the cost of managing
patients with mild or severe venous ulcers for the 2 y following
hospital discharge was estimated from a focused literature search
(Tables 2 and 3).
Sensitivity Analysis
We subjected each of our estimates to rigorous sensitivity
analysis using the ranges reported in Tables 2 and 3. In particular,
we were interested in the impact of variations within the following
variables: risk of DVT, the risk of a PE for patients with a DVT,
and the risk of mortality associated with a PE. We explored two
alternative estimates for the risk of developing a proximal DVT
after prophylactic VCF insertion from studies whose patient
populations closely matched our study cohort, but whose
methodologies were case series [8,28]. In our base case analysis,
we did not account for removal of VCF, which at our facility
(Foothills Medical Centre) costs Can$1,300 (Table 3). In sensitivity
analysis, we estimated the impact of removing VCF from all
patients who had no VTE at the time of hospital discharge.
Results
The baseline characteristics, short-term clinical outcomes and
associated costs of care for the cohort of trauma patients are shown
in Table 1. The mean age of the patients was 39.3 y and the
majority were male (76%). Motor vehicle collisions (60%) were the
most common mechanism of injury followed by falls (22%) and
violence (10%). The mean injury severity score of patients was 30.5,
and the mean abbreviated injury severity scores for the head/neck
and abdomen/pelvis were4.3 and 3.3 respectively. One-third of the
patients received surgery during their initial hospital stay. A total of
242 patients (24%) died before hospital discharge.
The results of the base case analysis are shown in Table 4. The
incidence of DVT at 12 wk was similar for the PCD (14.9%) and
SDU (15.0%) strategies, but was higher for the VCF (25.7%)
strategy. Conversely, the incidence of PE was highest in the PCD
strategy (2.9%), followed by the SDU (1.5%) and VCF (0.3%)
strategies. Mortality at 12 wk was similar for all three strategies.
All patients in the VCF strategy received a prophylactic VCF,
while a minority of patients in the PCD (5.5%) and SDU (11.5%)
strategies had VCFs inserted following the diagnosis of a DVT. Of
note, in one-third of the patients in the SDU strategy (4.2% of total
SDU cohort) with a VCF, it had been inserted following a false
positive test. Health care costs at 12 wk were Can$55,831 for the
PCD strategy, Can$55,334 for the SDU screening strategy, and
Can$57,377 for the VCF strategy. Over a lifetime analysis,
expected QALYs were similar for all three treatment strategies,
although costs remained highest for the VCF strategy. In the base
case analysis, the SDU screening strategy was dominant over the
other strategies, as it was associated with better clinical outcomes
and lower costs (both at 12 wk and over a lifetime time horizon).
Our analysis was not sensitive to plausible variations in the risk
of developing a proximal DVT after prophylactic insertion of a
Table 2. Base case probabilities and ranges considered.
Variable Subcategory Base Case Estimate
Range (95%
Confidence Interval) Reference
Incidence of proximal DVT No prophylaxis 18% at 21 d 14%–22% [2]
Prophylaxis with VCF alone OR 1.87 1.10–3.20 [7]
a
Pharmacological prophylaxis alone 6% at 14 d 2%–10% [17]
a
Incidence of PE in patients with
proximal DVT
No treatment 50% 625% [19]
Treatment with VCF alone 1.1% at 12 d 0.1%–3.9% [7]
a
Pharmacological treatment alone 4.8% at 12 d 2.2%–8.9% [7]
a
Fatality rate from PE 2.5% at 14 d 1.2%–4.6% [4]
Complication rates Risk of death from VCF insertion 0.12% 0.0%–0.3% [22]
Risk of mild to moderate PTS 23.7% 14%–21% [10]
Risk of severe PTS 7.0% 3%–6% [10]
Risk of major bleeding from therapeutic
anticoagulation
3.9% at 12 d 1.7%–7.5% [7]
a
Test characteristics Probability that a proximal DVT is symptomatic 50 625% [18]
Sensitivity of SDU in asymptomatic
patients with DVT
0.61 0.51–0.73 [1]
Specificity of SDU in asymptomatic
patients with DVT
0.97 0.95–0.99 [1]
Utility (a measure of overall
quality of life, range 0–1)
No VTE 0.691 — [23]
VTE with severe PTS 0.641 — [9,23]
Annual discount rate Costs 5% 0%–6% [39]
Utilities 5% 0%–6% [39]
aRandomised controlled trial.
Abbreviations: PTS, post-thrombotic syndrome.
doi:10.1371/journal.pmed.1000098.t002
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also not sensitive to plausible variation in the risk of death
associated with PE, or other variables. Moreover, the length of
time that pharmacological VTE prophylaxis was contraindicated
(2 or 4 wk) did not influence the results. In virtually all scenarios,
the SDU strategy was optimal, in that it resulted in the lowest costs
and best clinical outcomes. Removal of the VCF upon discharge
from hospital added Can$637 to the VCF strategy.
Discussion
Using decision analysis, we estimated the cost effectiveness of
three VTE prophylaxis strategies; PCD and expectant manage-
ment alone, weekly SDU screening and prophylactic insertion of a
VCF in all trauma patients with severe injuries and a
contraindication to pharmacological VTE prophylaxis for 2 wk.
The results demonstrate that prophylactic insertion of a VCF
results in a markedly higher incidence of DVTs and moderately
lower incidence of PEs. Patient mortality was not substantially
influenced by the VTE prophylaxis strategy. Weekly screening
with SDU was the optimal strategy, resulting in the best clinical
outcomes and lowest costs.
Our study provides further insight into the clinical implications
of VTE prevention strategies in trauma patients with severe
injuries who are at simultaneously high risk for thrombosis and
bleeding. First, critically ill trauma patients are unlikely to benefit
from routine prophylactic insertion of a VCF because the
attributable risk of death from PE is small and offset by the
potential risks of VCF insertion. A previous economic evaluation
by Brasel et al. [29] concluded that both ultrasound screening and
Table 3. Base case patient costing estimates.
Variable Subcategory Cost (CAN $) Range Tested Source/Reference
Inpatient Costs
Prophylaxis VCF insertion (includes cost of
two staff)
2,113 250% to +100% CHR microcosting [40]
VCF removal 1,300 CHR microcosting [40]
DU (bilateral) 240 CHR microcosting [40]
Heparin (prophylactic dosage)/wk 308 ADB List [41]
Physician fees (per patient) Mean weekly physician billings for
patients (sepsis) in the ICU
3,055 650% [42]
Mean weekly physician billings for
patients (sepsis) on the ward
280 650% [42]
Radiologist fee for DU scan 146 AMA fee schedule [43]
Radiologist fee for insertion of VCF 197 AMA fee schedule [43]
Cost of complications Major gastrointestinal bleed 9,195 [25]
Cost of early VTE-related readmissions DVT 4,413 [27]
PE 7,801 [27]
Post-discharge Health Care Costs
Monthly cost of outpatient anticoagulation 159 ADB List [9,41]
Annual cost of severe PT Year 1 6,729 [9,10]
Year 2 2,956 [9,10]
Annual cost of mild/moderate PTS Year 1 1,479 [9,10]
Year 2 601 [9,10]
Abbreviations: VCF, vena cava filter; CHR, Calgary Health Region; DU, Doppler ultrasound; ICU, intensive care unit; VTE, venous thromboembolism; DVT, deep venous
thrombosis; PE, pulmonary embolism; PTS, post-thrombotic syndrome; AMA, Alberta Medical Association; ADB, Alberta Drug Benefit.
doi:10.1371/journal.pmed.1000098.t003
Table 4. Clinical outcomes and costs for patients receiving three venous thromboembolism prophylaxis strategies.
Outcome Subcategory PCD SDU VCF
Outcomes at 12 wk DVT, % 14.9 15.0 25.7
PE, % 2.9 1.5 0.3
Mortality, % 24.5 24.4 24.5
VCF insertion, % 5.5 11.5 100
Cost of ICU, hospital and subsequent care, Can$ 55,831 55,334 57,377
Outcomes over patient lifetime Cost of ICU, hospital and subsequent care, Can$ 66,900 65,800 68,700
Expected QALYs 6.9 6.9 6.9
doi:10.1371/journal.pmed.1000098.t004
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Outcome
a PCDs SDU VCF
Base case
Deep vein thrombosis, % 14.9 15.0 25.7
Pulmonary embolism, % 2.9 1.5 0.3
Mortality, % 24.5 24.4 24.5
VCF insertion, % 5.5 11.5 100
Cost of ICU, hospital and subsequent care, Can$ 55,831 55,334 57,377
Low estimate risk of DVT in patients with VCF [28]
Deep vein thrombosis, % 14.9 14.6 14.6
Pulmonary embolism, % 2.9 1.5 0.2
Mortality, % 24.5 24.4 24.5
VCF insertion, % 5.5 11.5 100
Cost of ICU, hospital and subsequent care, Can$ 55,831 55,294 56,964
High estimate risk of DVT in patients with VCF [8]
Deep vein thrombosis, % 14.9 14.8 39.0
Pulmonary embolism, % 2.9 1.5 0.5
Mortality, % 24.5 24.4 24.6
VCF insertion, % 5.5 11.5 100
Cost of ICU, hospital and subsequent care, Can$ 55,831 55,313 58,428
Base case risk of DVT reduced by 25% in all strategies
Deep vein thrombosis, % 11.5 11.5 20.1
Pulmonary embolism, % 2.2 1.2 0.2
Mortality, % 24.4 24.4 24.5
VCF insertion, % 4.1 9.8 100
Cost of ICU, hospital and subsequent care, Can$ 55,523 55,509 57,166
Base case risk of DVT increased by 25% in all strategies
Deep vein thrombosis, % 18.2 18.3 30.9
Pulmonary embolism, % 3.6 1.9 0.3
Mortality, % 24.5 24.5 24.5
VCF insertion, % 6.9 13.1 100
Cost of ICU, hospital and subsequent care, Can$ 56,127 55,187 57,582
Base case risk of PE reduced by 50% in all strategies
Deep vein thrombosis, % 14.9 15.0 25.7
Pulmonary embolism, % 1.6 0.8 0.1
Mortality, % 24.4 24.4 24.5
VCF insertion, % 5.2 11.4 100
Cost of ICU, hospital and subsequent care, Can$ 55,855 55,072 57,384
Base case risk of PE increased by 50% in all strategies
Deep vein thrombosis, % 14.9 15.0 25.7
Pulmonary embolism, % 4.0 2.2 0.4
Mortality, % 24.5 24.5 24.5
VCF insertion, % 5.9 11.6 100
Cost of ICU, hospital and subsequent care, Can$ 55,814 55,577 57,370
Base case risk of death from PE reduced to 1% in all strategies
b
Deep vein thrombosis, % 14.9 15.0 25.7
Pulmonary embolism, % 2.9 1.5 0.3
Mortality, % 24.4 24.4 24.5
VCF insertion, % 5.5 11.5 100
Cost of ICU, hospital and subsequent care, Can$ 55,850 55,347 57,380
Base case risk of death from PE increased to 10% in all strategies
b
Deep vein thrombosis, % 14.9 15.0 25.7
VTE Prophylaxis in Trauma Patients
PLoS Medicine | www.plosmedicine.org 7 June 2009 | Volume 6 | Issue 6 | e1000098insertion of a VCF are effective at preventing PE in high-risk ICU
patients. However, their study assumed that patients were
concurrently managed with pharmacological VTE prophylaxis
and that the risk of death from a treated PE was 8% and 32% for
an untreated PE. Although, many studies in the literature quote
the risk of death in patients with PE as being as high as 30% [1],
the risk of death is often reported over the subsequent year and the
cause of death in the vast majority of these patients is the
underlying condition predisposing to the PE (malignancy,
infection, cardiac disease) [4], rather than the PE itself. Second,
the optimal VTE prophylaxis strategy in critically ill trauma
patients with a contraindication to pharmacological VTE
prophylaxis is early diagnosis of DVT. Nevertheless, screening
SDU is limited by the operating characteristics of the test in
asymptomatic trauma patients with a small number of patients
receiving false positive tests and a larger number of patients false
negative tests. Third, clinicians caring for trauma patients with
severe injuries need to re-evaluate on a daily basis the risk tradeoff
of bleeding and thrombosis in their high-risk patients. Currently
the best scientific evidence for VTE prophylaxis is for pharma-
cological prophylaxis, yet there is very little evidence to guide
clinicians about when it is safe to initiate pharmacological VTE
prophylaxis in trauma patients with injuries characterized by high
risk for serious bleeding complications [1,14]. In fact, current
evidence suggests that considerable practice variation exists as to
the timing of initiation of pharmacological VTE prophylaxis in
trauma patients with severe injuries and that randomized
controlled studies are urgently needed to answer this important
question [14,30]. Fourth, consideration should be given to revising
VTE prophylaxis protocols to reflect the likely boundaries of
therapeutic strategies pending data from definitive studies. A
review of the literature suggests that prophylactic insertion of a
VCF is included in the standard VTE prophylaxis protocols of
many trauma centres [31] and that utilization has increased over
time [11,32,33,34]. Amending VTE prophylaxis protocols to
exclude prophylactic insertion of a VCF while emphasizing DVT
screening and early initiation of pharmacological prophylaxis is
likely to reduce the incidence of DVT and improve patient
outcomes.
Those unfamiliar with decision analysis may find the modelling
and statistical techniques to be complex and non-transparent. It
should be noted that the most important sources of data for our
model (risk of DVT, risk of PE) come from high-quality
randomized trials. Moreover, using these high-quality estimates,
a simple calculation can approximate the results of our Markov
analysis. The attributable risk of death from PE in the PCD and
VCF strategies are very small and can be estimated as 0.22% (18%
risk of DVT650% risk of PE in a patient who develops
DVT62.5% risk of death in a patient who develops PE) and
0.13% (29% risk of DVT61.1% risk of PE in a patient who
develops DVT62.5% risk of death in a patient who develops
PE+0.12% risk of death from VCF insertion), respectively. On the
cost side, there is an immediate cost of Can$2,300 for VCF
insertion and Can$1,300 for removal. The results are similar to
those reported in Table 4 with differences primarily related to the
clinical diagnosis of DVT in the PCD strategy and treatment with
VCF or anticoagulation. Compared to SDU, prophylaxis of 100
patients with VCF would be expected to yield an additional 11
proximal DVTs, but prevent one PE at an extra cost of
Can$204,300 (1006Can$57,3772Can$55,334) over 12 wk.
The results of our study need to be interpreted within the
context of its limitations. First, our results are based on an
economic analysis of patients admitted to a medical–surgical ICU
at a regional trauma centre in Canada. It is unknown whether the
results of an economic analysis performed in one centre or country
can be generalized to others [35]. However, our cohort of patients
Outcome
a PCDs SDU VCF
Pulmonary embolism, % 2.9 1.5 0.3
Mortality, % 24.8 24.6 24.7
VCF insertion, % 5.5 11.4 100
Cost of ICU, hospital and subsequent care, Can$ 55,737 55,271 57,362
Pharmacological prophylaxis contraindication increased to 4 wk duration in all strategies
Deep vein thrombosis, % 17.1 17.6 29.0
Pulmonary embolism, % 3.3 1.6 0.3
Mortality, % 24.5 24.5 24.5
VCF insertion, % 9.1 18.3 100
Cost of ICU, hospital and subsequent care, Can$ 55,996 56,562 57,369
VCF removal upon discharge from hospital
c
Deep vein thrombosis, % 14.9 15.0 25.7
Pulmonary embolism, % 2.9 1.5 0.3
Mortality, % 24.5 24.4 24.5
VCF insertion, % 5.5 11.5 100
Cost of ICU, hospital and subsequent care, Can$ 55,831 55,334 58,014
Expected QALYs were 6.9 for all three strategies for all sensitivity analyses.
aAll outcomes are reported at 12 wk.
bBase-line risk of death from PE in model is 2.5%.
cVCF removed from patients discharged home from hospital with no VTE in VCF strategy alone at cost $1,300.
doi:10.1371/journal.pmed.1000098.t005
Table 5. cont.
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to those reported for trauma patients with severe injuries admitted
to trauma centres in other developed countries [36,37,38].
Second, our results are based on a contraindication to pharma-
cological VTE prophylaxis that includes injuries and a timeframe
that not all clinicians will agree with. Nevertheless, a less
conservative definition of contraindications to pharmacological
VTE prophylaxis allowing more patients to receive pharmacolog-
ical prophylaxis earlier following injury would only make insertion
of VCF look less efficacious and less cost effective. Despite these
limitations, a strength of our analysis is that key variable estimates
were derived from a systematic review of the literature and based
on high-quality randomized controlled trials, and that the results
were robust to plausible variation in the risk of all tested variables,
suggesting that similar findings would be likely in other settings.
Conclusion
Venous thromboembolism is a common complication in trauma
patients with severe injuries. However, the attributable mortality
due to PE in this patient population appears to be small.
Prophylactic placement of VCF in patients at high risk of VTE
who cannot receive pharmacological prophylaxis is expensive, is
associated with an increased risk of DVT, and should not be
routinely performed. Strategies employing screening with SDU
appear more effective and less expensive.
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Background. For patients who have been seriously injured
in an accident or a violent attack (trauma patients), venous
thromboembolism (VTE)—the formation of blood clots that
limit the flow of blood through the veins—is a frequent and
potentially fatal complication. The commonest form of VTE is
deep vein thrombosis (DVT). ‘‘Distal’’ DVTs (clots that form in
deep veins below the knee) affect about half of patients with
severe trauma; ‘‘proximal’’ DVTs (clots that form above the
knee) develop in one in five trauma patients. DVTs cause
pain and swelling in the affected leg and can leave patients
with a painful condition called post-thrombotic syndrome.
Worse still, part of the clot can break off and travel to the
lungs where it can cause a life-threatening pulmonary
embolism (PE). Distal DVTs rarely embolize but, if
untreated, half of patients who present with a proximal
DVT will develop a PE, and 2%–3% of them will die as a
result.
Why Was This Study Done? VTE is usually prevented by
using heparin, a drug that stops blood clotting, but clinicians
treating critically ill trauma patients have a dilemma. Many of
these patients are at high risk of serious bleeding
complications so cannot be given heparin to prevent VTE.
Nonpharmacological ways to prevent VTE include the use of
pneumatic compression devices to keep the blood moving
in the legs (clots often form in patients confined to bed
because of the sluggish blood flow in their legs), repeated
screening for blood clots using Doppler ultrasound, and the
insertion of a ‘‘vena cava filter’’ into the vein that takes blood
from the legs to the heart. This last device catches blood
clots before they reach the lungs but increases the risk of
DVT. Unfortunately, no-one knows which VTE prevention
strategy works best in trauma patients who cannot be given
heparin. In this study, therefore, the researchers use decision
analysis (the systematic evaluation of the most important
factors affecting a decision) to estimate the costs and likely
clinical outcomes of these strategies.
What Did the Researchers Do and Find? The researchers
used cost and clinical data from patients admitted to a
Canadian trauma center with severe head/neck and/or
abdomen/pelvis injuries (patients with a high risk of
bleeding complications likely to make heparin therapy
dangerous for up to two weeks after the injury) to
construct a Markov decision analysis model. They then fed
published data on the chances of patients developing DVT
or PE, and on the effectiveness of the three VTE prevention
strategies, into the model to obtain estimates of the costs
and clinical outcomes of the strategies at 12 weeks after the
injury and over the patients’ lifetime. The estimated
incidence of DVT at 12 weeks was 15% for the pneumatic
compression device and Doppler ultrasound strategies, but
25% for the vena cava filter strategy. By contrast, the
estimated incidence of PE was 2.9% with the pneumatic
compression device, 1.5% with Doppler ultrasound, but only
0.3% with the vena cava filter. The expected mortality with
all three strategies was similar. Finally, the estimated health
care costs per patient at 12 weeks were Can$55,334 and
Can$55,831 for the Doppler ultrasound and pneumatic
compression device strategies, respectively, but Can$57,377
for the vena cava filter strategy; similar trends were seen for
lifetime health care costs.
What Do These Findings Mean? As with all mathematical
models, these findings depend on the data fed into the
model and on the assumptions included in it. For example,
because data from one Canadian trauma unit were used to
construct the model, these findings may not be
generalizable. Nevertheless, these findings suggest that,
although VTE is common among patients with severe
injuries, PE is not a major cause of death among these
patients. They also suggest that the use of vena cava filters
for VTE prevention in patients who cannot receive heparin
should not be routinely used because it is expensive and
increases the risk of DVT. Finally, these results suggest that,
compared with the other strategies, serial Doppler
ultrasound is associated with better clinical outcomes and
lower costs.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000098.
N The US National Heart Lung and Blood Institute provides
information (including an animation) on deep vein
thrombosis and pulmonary embolism
N MedlinePlus provides links to more information about
deep vein thrombosis and pulmonary embolism (in several
languages)
N The UK National Health Service Choices Web site has
information on deep vein thrombosis and on embolism (in
English and Spanish)
N The Eastern Association for the Surgery of Trauma working
group document ‘‘Practice Management Guidelines for the
Management of Venous Thromboembolism in Trauma
Patients’’ can be downloaded from the Internet
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